A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope

• Published in: bioRxiv
• Main Authors: VanBlargan, Laura, Adams, Lucas, Liu, Zhuoming, Chen, Rita E, Gilchuk, Pavlo, Raju, Saravanan, Smith, Brittany, Zhao, Haiyan, Case, James Brett, Winkler, Emma S, Whitener, Bradley, Droit, Lindsay, Aziati, Ismael, Shi, Pei-Yong, Creanga, Adrian, Pegu, Amarendra, Handley, Scott, Wang, David, Boon, Adrianus, Crowe, James E, Whelan, Sean P J, Fremont, Daved, Diamond, Michael
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 26.04.2021; Cold Spring Harbor Laboratory
• Edition: 1.1
• Subjects: ACE2; Angiotensin; Angiotensin-converting enzyme 2; Biotechnology; Epitopes; Funding; Laboratories; Microbiology; Monoclonal antibodies; Peptidyl-dipeptidase A; Pharmacology; Severe acute respiratory syndrome coronavirus 2; Spike protein; Strains (organisms); Transgenic mice; Vaccines; Virus attachment

With the emergence of SARS-CoV-2 variants with increased transmissibility and potential resistance, antibodies and vaccines with broadly inhibitory activity are needed. Here we developed a panel of neutralizing anti-SARS-CoV-2 mAbs that bind the receptor binding domain of the spike protein at distin...